A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda

Luo, Jia; Nishikawa, Go; Prasad, Vinay

doi:10.1007/s00432-019-02984-2

Cited by 8 publications

(5 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few immunotherapy drugs based on the programmed cell death protein 1/programmed death-ligand 1 (PD1/ PDL1) immune checkpoint have been approved by the Food and Drug Administration (FDA) for many tumors (7)(8)(9). Nevertheless, little research and limited achievements have been made in immunotherapy for EC to date.…”

Section: Introductionmentioning

confidence: 99%

Immune-related gene ANGPT1 is an adverse biomarker for endometrial carcinoma

Nong¹,

Su²,

Jin³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: Immunotherapy has made great strides in cancer treatment. Endometrial carcinoma (EC) has been 1 of the most common tumors among women. This study aimed to screen immune-related prognosis biomarkers for EC. Methods:The transcriptome profiling and clinical data of EC were downloaded from The Carcinoma Genome Atlas (TCGA) public database, and differentially expressed genes (DEGs) were obtained through the limma package in R software. An immune-related genes (IRGs) list was collected from the ImmPort database. We constructed a free-scale gene co-expression network via weighted gene co-expression network analysis (WGCNA). Then, the intersection genes of the module genes which significantly related to EC, along with IRGs and DEGs were screened as the candidate genes for further analysis. We identified the hub gene via Venn analysis of the protein-protein interaction (PPI) network genes and the prognostic genes, and verified expression of the hub gene through Human Protein Atlas (HPA) and Gene Expression Omnibus (GEO) databases which provided the GSE17025 dataset. Furthermore, we used the CIBERSORT deconvolution algorithm to explore tumor immune cells infiltration in EC, and investigated correlations between the hub gene and immune cells. Results:The differential expression analysis demonstrated that there were 900 up-regulated genes and 1,008 down-regulated genes in TCGA-UCEC (Uterine Corpus Endometrial Carcinoma) cohort. There were 74 candidate intersection genes in blue module genes, IRGs, and DEGs. Finally, angiopoietin 1 (ANGPT1) was identified as the hub gene in EC. Low expression of ANGPT1 was associated with better overall survival (OS) in EC patients. The expression of ANGPT1 was negatively correlated with regulatory T cells (Tregs), but positively correlated with resting memory cluster of differentiation 4 (CD4) T cells, activated dendritic cells (DCs), activated natural killer (NK) cells, and activated memory CD4 T cells (P<0.05, Spearman). A highinfiltrating regulatory T cell would improve the prognosis for EC patients. Conclusions:The gene ANGPT1 can increase the infiltration of T cells and improve the prognosis of EC patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Immune-related gene ANGPT1 is an adverse biomarker for endometrial carcinoma

Nong¹,

Su²,

Jin³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…In recent years, the role of tumor microenvironment in the occurrence and development of liver cancer has been widely recognized [19,20]. Programmed death ligand-1 (PD-L1), a microenvironment transmembrane protein, is an immune checkpoint factor participating in immune surveillance and exerting suppressive effects on the immune system [21][22][23]. Inhibition of the PD-1/PD-L1 pathway has proven effective in many types of cancer, including HCC.…”

Section: Agingmentioning

confidence: 99%

Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma

Jiang

Shi

Zheng

et al. 2020

Aging

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a heterogeneous malignancy with gender-related differences in onset and course. Androgen receptor (AR), a male hormone receptor, is critical in the initiation and progression of HCC. The role of AR in HCC has been mechanistically characterized and anti-AR therapies have been developed, showing limited efficacy. Immunotherapy targeting immune checkpoint proteins may substantially improve the clinical management of HCC. The mechanism by which AR influences HCC immune state remains unclear. In this study, we demonstrated that AR negatively regulated PD-L1, by acting as a transcriptional repressor of PD-L1. Notably, AR over-expression in HCC cells enhanced CD8 + T function in vitro. We then verified the AR/PD-L1 correlation in patients. In animal experiment we found that lower AR expressed tumor achieved better response to PD-L1 inhibitor. Thus, AR suppressed PD-L1 expression, possibly contributing to gender disparity in HCC. Better understanding of the roles of AR during HCC initiation and progression will provide a novel angle to develop potential HCC immunotherapies.

show abstract

“…Currently, commonly considered targets for tumor therapy include CD20, HER2, VEGF, EGFR, KIT, etc. [4,5]. Drugs designed for the above targets have already entered clinical application and participated in the management of carcinoma, such as imatinib, bevacizumab, and cetuximab [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy

Liu,

Wang

et al. 2024

Cancer Cell Int

View full text Add to dashboard Cite

Translationally controlled tumor protein (TCTP), also known as histamine-releasing factor (HRF) or fortilin, is a highly conserved protein found in various species. To date, multiple studies have demonstrated the crucial role of TCTP in a wide range of cellular pathophysiological processes, including cell proliferation and survival, cell cycle regulation, cell death, as well as cell migration and movement, all of which are major pathogenic mechanisms of tumorigenesis and development. This review aims to provide an in-depth analysis of the functional role of TCTP in tumor initiation and progression, with a particular focus on cell proliferation, cell death, and cell migration. It will highlight the expression and pathological implications of TCTP in various tumor types, summarizing the current prevailing therapeutic strategies that target TCTP.

show abstract

A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda

Cited by 8 publications

References 25 publications

Immune-related gene ANGPT1 is an adverse biomarker for endometrial carcinoma

Immune-related gene ANGPT1 is an adverse biomarker for endometrial carcinoma

Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma

Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy

Contact Info

Product

Resources

About